BidaskClub cut shares of NxStage Medical (NASDAQ:NXTM) from a sell rating to a strong sell rating in a research report released on Thursday.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded NxStage Medical from a sell rating to a hold rating in a research note on Wednesday, January 3rd. ValuEngine lowered NxStage Medical from a hold rating to a sell rating in a report on Friday, February 2nd. Finally, Northland Securities reaffirmed a hold rating and set a $30.00 target price on shares of NxStage Medical in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. The company currently has an average rating of Hold and a consensus price target of $30.25.
Shares of NxStage Medical (NASDAQ NXTM) opened at $24.62 on Thursday. NxStage Medical has a 52 week low of $20.45 and a 52 week high of $30.80. The stock has a market capitalization of $1,630.63, a PE ratio of -351.71 and a beta of -0.08.
Hedge funds have recently bought and sold shares of the business. Cowen Inc. purchased a new position in NxStage Medical during the 3rd quarter valued at about $1,908,000. Bank of Montreal Can grew its holdings in shares of NxStage Medical by 15.5% during the fourth quarter. Bank of Montreal Can now owns 572,868 shares of the medical device company’s stock worth $13,880,000 after purchasing an additional 77,082 shares in the last quarter. Gabelli Funds LLC purchased a new position in shares of NxStage Medical during the third quarter worth about $4,941,000. JPMorgan Chase & Co. grew its holdings in shares of NxStage Medical by 239,738.6% during the third quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock worth $51,502,000 after purchasing an additional 1,869,961 shares in the last quarter. Finally, ARP Americas LLC purchased a new position in shares of NxStage Medical during the third quarter worth about $11,219,000. 84.37% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/02/19/bidaskclub-downgrades-nxstage-medical-nxtm-to-strong-sell.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.